This video is available for 0.25 AMA PRA Category 1 Credit(s)™

Click here to view CME and claim credit: https://www.francefoundation.com/asth...

Watch as Dr. Nicola Hanania summarizes a recent study looking at "Omalizumab to Reduce or Prevent Exacerbations," and gives his take on what this means for clinical practice.

For more education from this series click here: https://www.francefoundation.com/asth...

Faculty Disclosures
Jonathan Corren, MD, has served on the speakers bureau for AstraZeneca, Genentech, and Teva. He has also participated in contract research for 3M, Aimmune Therapeutics, Genentech, Regeneron, and Sanofi.

Nicola Hanania, MD, MS, has served as a consultant for AstraZeneca, Genentech, GlaxoSmithKline, Gossamer Bio, Mylan, Novartis, Regeneron, Roche, and Sanofi. He has also participated in contract research for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, Genentech, GlaxoSmithKline, Novartis, and Sanofi.

The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

This information is intended for health care providers.

This activity is supported by an educational grant from Genentech.